NASDAQ:INO - Nasdaq - US45773H4092 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to INO. INO was compared to 558 industry peers in the Biotechnology industry. While INO seems to be doing ok healthwise, there are quite some concerns on its profitability. INO is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -110.55% | ||
ROE | -188.25% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -30.28 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.63 | ||
Quick Ratio | 2.63 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.39
+0.02 (+1.46%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 250.21 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.38 | ||
P/tB | 1.38 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -110.55% | ||
ROE | -188.25% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 14.83% | ||
Cap/Sales | 180.71% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.63 | ||
Quick Ratio | 2.63 | ||
Altman-Z | -30.28 |